Race and insurance differences in the receipt of adjuvant chemotherapy among patients with stage III colon cancer

Journal of Clinical Oncology

Volumn 33, Issue 23, 2015, Pages 2530-2536

  Murphy, Caitlin C ^a   Harlan, Linda C ^b   Warren, Joan L ^b   Geiger, Ann M ^b  

^a The University of North Carolina at Chapel Hill   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; COLON CANCER; DISEASE SEVERITY; EUROPEAN AMERICAN; FEMALE; HEALTH INSURANCE; HUMAN; MALE; MEDICAID; MEDICARE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; CANCER REGISTRY; CANCER STAGING; CAUCASIAN; COLONIC NEOPLASMS; ECONOMICS; EPIDEMIOLOGY; ETHNOLOGY; INSURANCE; ODDS RATIO; PATHOLOGY; RISK; STATISTICS AND NUMERICAL DATA;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MEDICAID; MEDICARE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; RISK; SAMPLING STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84940368521     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.3026     Document Type: Article

References (61)

1. National Cancer Institute: surveillance, epidemiology, and end results. Cancer Statistics Review 1975-2011. 2013
2. Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104-117, 2014
3. Robbins AS, Siegel RL, Jemal A: Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol 30:401-405, 2012
4. Doubeni CA, Major JM, Laiyemo AO, et al: Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst 104:1353-1362, 2012
5. Doubeni CA, Laiyemo AO, Major JM, et al: Socioeconomic status and the risk of colorectal cancer: An analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer 118:3636-3644, 2012
6. Siegel RL, Jemal A, Thun MJ, et al: Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. J Natl Med Assoc 100:1441-1444, 2008
7. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al: Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev 21:728-736, 2012
8. Klabunde CN, Cronin KA, Breen N, et al: Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev 20:1611-1621, 2011
9. Doubeni CA, Field TS, Buist DS, et al: Racial differences in tumor stage and survival for colorectal cancer in an insured population. Cancer 109:612-620, 2007
10. Laiyemo AO, Doubeni C, Pinsky PF, et al: Race and colorectal cancer disparities: Health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst 102:538-546, 2010
11. Alexander D, Jhala N, Chatla C, et al: High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer 103:2163-2170, 2005
12. Shavers VL: Racial/ethnic variation in the anatomic subsite location of in situ and invasive cancers of the colon. J Natl Med Assoc 99:733-748, 2007
13. Johnson H Jr., Carstens R: Anatomical distribution of colonic carcinomas. Interracial differences in a community hospital population. Cancer 58:997-1000, 1986
14. Francois F, Park J, Bini EJ: Colon pathology detected after a positive screening flexible sigmoidoscopy: A prospective study in an ethnically diverse cohort. Am J Gastroenterol 101:823-830, 2006
15. Fairley TL, Cardinez CJ, Martin J, et al: Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. Cancer 107:1153-1161, 2006
16. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
17. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447-1456, 1989
18. Windle R, Bell PR, Shaw D: Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 74:569-572, 1987
19. NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
20. Potosky AL, Harlan LC, Kaplan RS, et al: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192-1202, 2002
21. Cronin DP, Harlan LC, Potosky AL, et al: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101:2308-2318, 2006
22. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999
23. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23: 8671-8678, 2005
24. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
25. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
26. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
27. Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471, 2011
28. Schmoll HJ, Cartwright T, Tabernero J, et al: Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. J Clin Oncol 25:102-109, 2007
29. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704, 2005
30. Benson AB 3rd, Venook AP, Bekaii-Saab T, et al: Colon cancer, version 3.2014. J National Comprehensive Cancer Network 12:1028-1059, 2014
31. Baldwin LM, Dobie SA, Billingsley K, et al: Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97:1211-1220, 2005
32. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
33. Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294:2703-2711, 2005
34. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
35. Pan W: Akaike's information criterion in generalized estimating equations. Biometrics 57:120-125, 2001
36. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
37. Ekwueme DU, Yabroff KR, Guy GP, Jr., et al: Medical costs and productivity losses of cancer survivors-United States, 2008-2011. MMWR Morb Mortal Wkly Rep 63:505-510, 2014
38. Guy GP, Jr., Ekwueme DU, Yabroff KR, et al: Economic burden of cancer survivorship among adults in the United States. J Clin Oncol 31:3749-3757, 2013
39. Kent EE, Forsythe LP, Yabroff KR, et al: Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119:3710-3717, 2013
40. Dowling EC, Chawla N, Forsythe LP, et al: Lost productivity and burden of illness in cancer survivors with and without other chronic conditions. Cancer 119:3393-3401, 2013
41. Yabroff KR, Lund J, Kepka D, et al: Economic burden of cancer in the United States: Estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 20:2006-2014, 2011
42. Ramsey S, Blough D, Kirchhoff A, et al: Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32:1143-1152, 2013
43. The Henry J. Kaisure Family Foundation, Kaiser Commission on Medicaid and the Uninsured: Medicaid's role for black Americans. http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8188.pdf
44. United States Bureau of Labor Statistics: Unemployment rates by race and ethnicity, 2010. http://www.bls.gov/opub/ted/2011/ted-20111005.htm
45. Chirikos TN, Roetzheim RG, McCarthy EP, et al: Cost disparities in lung cancer treatment by disability status, sex, and race. Disabil Health J 1:108-115, 2008
46. Jayadevappa R, Malkowicz SB, Chhatre S, et al: Racial and ethnic variation in health resource use and cost for prostate cancer. BJU Int 106:801-808, 2010
47. Pisu M, Azuero A, Meneses K, et al: Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI). Breast Cancer Res Treat 127:521-529, 2011
48. Weaver KE, Rowland JH, Bellizzi KM, et al: Forgoing medical care because of cost: Assessing disparities in healthcare access among cancer survivors living in the United States. Cancer 116:3493-3504, 2010
49. Schrag D: The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
50. Mayer RJ: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 25:4165-4167, 2007
51. Gupta S, Jain P, Gupta S, et al: 5-flourouracil (5FU) shortage: Clinical implications and costs in a single month. J Clin Oncol 30:abstr 663, 2012
52. Balogh E, Patlak M, Nass SJ: Delivering Affordable Cancer Care in the 21st Century: Workshop Summary, National Academies Press, 2013.
53. The Henry J. Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured: Medicaid spending growth and the great recession, 2007-2009. http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8157.pdf
54. Shankaran V, Jolly S, Blough D, et al: Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: A population-based exploratory analysis. J Clin Oncol 30:1608-1614, 2012
55. White A, Liu CC, Xia R, et al: Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002. Cancer 113:3400-3409, 2008
56. Davidoff AJ, Rapp T, Onukwugha E, et al: Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: The role of the medical oncologist evaluation. Med Care 47: 1229-1236, 2009
57. Haas JS, Brawarsky P, Iyer A, et al: Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality. Cancer 117:4267-4276, 2011
58. Hao Y, Landrine H, Jemal A, et al: Race, neighbourhood characteristics and disparities in chemotherapy for colorectal cancer. J Epidemiol Community Health 65:211-217, 2011
59. Gross CP, Smith BD, Wolf E, et al: Racial disparities in cancer therapy: Did the gap narrow between 1992 and 2002? Cancer 112:900-908, 2008
60. Zuckerman S, Williams AF, Stockley KE: Trends in Medicaid physician fees, 2003-2008. Health Aff (Millwood) 28:w510-519, 2009
61. Schoenman J, Feldman J: Results of the Medicare Payment Advisory Commission's 2002 survey of physicians. Bethesda (MD), The Project HOPE Center for Health Affairs, 2002